Teleflex Incorporated (NYSE:TFX) has been given an average recommendation of “Hold” by the twelve brokerages that are covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, five have issued a hold recommendation and six have assigned a buy recommendation to the company. The average twelve-month price objective among analysts that have covered the stock in the last year is $283.63.
TFX has been the subject of a number of analyst reports. Needham & Company LLC raised their price target on shares of Teleflex from $237.00 to $285.00 and gave the stock a “buy” rating in a research note on Friday, November 3rd. Jefferies Group raised their price objective on shares of Teleflex from $270.00 to $295.00 and gave the stock a “buy” rating in a report on Friday, November 3rd. Morgan Stanley raised their price objective on shares of Teleflex from $274.00 to $290.00 and gave the stock an “equal weight” rating in a report on Friday, November 3rd. Piper Jaffray Companies began coverage on shares of Teleflex in a report on Friday, November 10th. They set an “overweight” rating and a $295.00 price objective for the company. Finally, Deutsche Bank lowered shares of Teleflex from a “buy” rating to a “hold” rating and set a $251.00 price objective for the company. in a report on Tuesday, November 14th.
Shares of Teleflex (TFX) traded up $5.77 on Tuesday, reaching $255.21. 348,171 shares of the company’s stock were exchanged, compared to its average volume of 296,133. The company has a market capitalization of $12,163.30, a PE ratio of 46.67, a price-to-earnings-growth ratio of 1.99 and a beta of 1.15. The company has a current ratio of 4.72, a quick ratio of 3.70 and a debt-to-equity ratio of 0.88. Teleflex has a 1 year low of $183.92 and a 1 year high of $288.78.
Teleflex (NYSE:TFX) last announced its quarterly earnings results on Thursday, February 22nd. The medical technology company reported $2.44 EPS for the quarter, topping analysts’ consensus estimates of $2.40 by $0.04. The firm had revenue of $595.10 million during the quarter, compared to analysts’ expectations of $601.17 million. Teleflex had a net margin of 12.41% and a return on equity of 16.27%. The company’s revenue for the quarter was up 15.8% compared to the same quarter last year. During the same quarter last year, the company earned $2.13 earnings per share. analysts expect that Teleflex will post 8.36 earnings per share for the current fiscal year.
The company also recently disclosed a quarterly dividend, which will be paid on Thursday, March 15th. Stockholders of record on Friday, March 2nd will be issued a dividend of $0.34 per share. This represents a $1.36 annualized dividend and a dividend yield of 0.53%. The ex-dividend date of this dividend is Thursday, March 1st. Teleflex’s payout ratio is 24.82%.
In related news, Director Stephen K. M.D. Klasko sold 200 shares of the firm’s stock in a transaction that occurred on Friday, December 1st. The shares were sold at an average price of $265.32, for a total value of $53,064.00. Following the completion of the sale, the director now owns 8,080 shares of the company’s stock, valued at $2,143,785.60. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director George Babich, Jr. sold 2,500 shares of the firm’s stock in a transaction that occurred on Tuesday, January 16th. The shares were sold at an average price of $263.38, for a total transaction of $658,450.00. Following the completion of the sale, the director now directly owns 10,583 shares of the company’s stock, valued at approximately $2,787,350.54. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 10,100 shares of company stock valued at $2,671,994. Company insiders own 2.39% of the company’s stock.
Several institutional investors have recently modified their holdings of TFX. American Century Companies Inc. increased its holdings in shares of Teleflex by 41.6% in the third quarter. American Century Companies Inc. now owns 1,187,909 shares of the medical technology company’s stock valued at $287,438,000 after purchasing an additional 348,829 shares in the last quarter. William Blair Investment Management LLC acquired a new stake in shares of Teleflex in the fourth quarter valued at approximately $53,163,000. Renaissance Technologies LLC increased its holdings in shares of Teleflex by 511.6% in the fourth quarter. Renaissance Technologies LLC now owns 195,700 shares of the medical technology company’s stock valued at $48,694,000 after purchasing an additional 163,700 shares in the last quarter. BlackRock Inc. increased its holdings in shares of Teleflex by 3.4% in the fourth quarter. BlackRock Inc. now owns 4,709,341 shares of the medical technology company’s stock valued at $1,171,779,000 after purchasing an additional 156,527 shares in the last quarter. Finally, Redmile Group LLC increased its holdings in shares of Teleflex by 449.9% in the fourth quarter. Redmile Group LLC now owns 172,486 shares of the medical technology company’s stock valued at $42,918,000 after purchasing an additional 141,121 shares in the last quarter. 88.98% of the stock is owned by institutional investors and hedge funds.
ILLEGAL ACTIVITY NOTICE: This piece of content was first published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this piece of content on another publication, it was illegally stolen and reposted in violation of U.S. & international copyright and trademark law. The correct version of this piece of content can be accessed at https://www.dispatchtribunal.com/2018/02/23/teleflex-incorporated-tfx-receives-286-25-consensus-price-target-from-analysts.html.
Teleflex Company Profile
Teleflex Incorporated is a provider of medical technology products. The Company designs, develops, manufactures and supplies single-use medical devices used by hospitals and healthcare providers for diagnostic and therapeutic procedures in critical care and surgical applications. The Company operates through six segments: Vascular North America; Anesthesia North America; Surgical North America; Europe, the Middle East and Africa (EMEA); Asia, and Original Equipment Manufacturer (OEM).
Receive News & Ratings for Teleflex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teleflex and related companies with MarketBeat.com's FREE daily email newsletter.